J.P. Morgan Upgrades H.B. Fuller to Overweight, Sees 14% EBITDA Gain
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
hb-fullerjpmorgan-upgrade
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
H.B. Fuller Company’s shares received an upgrade to Overweight from Neutral by J.P. Morgan on June 26, 2026. The firm set a price target of $105, implying over 20% upside from recent trading levels. Key to the firm’s upgrade is a forecast for the adhesive manufacturer’s EBITDA to grow by approximately 14% in fiscal 2027. The analyst cited improved visibility on raw material cost trends and sustained pricing power in key end-markets as the rationale for the revised view.
Analyst upgrades for mid-cap specialty chemical stocks have been scarce in the first half of 2026. The sector has faced persistent headwinds from volatile raw material costs and weaker demand in construction-related segments. The last comparable major upgrade for a U.S. adhesives peer occurred in October 2025, when Deutsche Bank raised its rating on RPM International.
The current macro backdrop features the Federal Reserve holding its benchmark rate steady at 5.50%, maintaining pressure on industrial capital expenditure. The catalyst for J.P. Morgan’s reassessment now is a pronounced stabilization in key input costs like ethylene and propylene over the past quarter. This stability, combined with H.B. Fuller’s completed portfolio realignment towards higher-margin engineering adhesives, provides a clearer path for margin expansion.
H.B. Fuller’s stock closed at $86.42 on the session prior to the upgrade announcement. The new $105 price target represents a 21.5% increase from that level. The company’s market capitalization stands at approximately $4.7 billion. J.P. Morgan’s FY2027 EBITDA estimate of $720 million compares to a consensus estimate of $680 million and an expected FY2026 result near $632 million.
| Metric | Prior JPM View (Neutral) | New JPM View (Overweight) | Change |
|---|---|---|---|
| Rating | Neutral | Overweight | Upgrade |
| Price Target | Not Disclosed | $105 | +21.5% from $86.42 |
| FY2027 EBITDA Est. | ~$680M consensus | ~$720M | +$40M vs. consensus |
The projected 14% EBITDA growth for FY2027 significantly outpaces the estimated 3-5% growth for the broader S&P 500 Materials sector. H.B. Fuller’s forward price-to-earnings ratio of 15.2x is now at a 10% discount to its five-year historical average.
The upgrade signals a growing divergence in chemical sector analysis, favoring companies with demonstrated pricing power over pure commodity exposure. Primary beneficiaries of this thematic shift include peers like RPM International, Quaker Houghton, and GCP Applied Technologies. These firms could see valuation re-ratings of 5-10% if H.B. Fuller’s margin trajectory materializes.
Conversely, more commodity-exposed chemical names like LyondellBasell and Westlake Chemical face incremental pressure as capital rotates towards specialty players. A key limitation to the bullish thesis is H.B. Fuller’s sensitivity to a potential sharp recession in European industrial markets, which contribute 25% of revenue. Positioning data indicates institutional investors have been net sellers of chemical stocks for three consecutive quarters, making this upgrade a potential early signal of renewed long interest from major desks.
H.B. Fuller is scheduled to report its Q3 FY2026 earnings on September 24, 2026. Investors will scrutinize gross margin figures for confirmation of the input cost stabilization thesis. The next major industry catalyst is the American Coatings Show in early October 2026, which will provide demand commentary from distributors.
Key technical levels to monitor include chart resistance at the 200-day moving average near $92.50 and prior support at $80. A sustained break above the $92.50 level would likely confirm the upgrade-driven momentum. Should raw material indices like the ICIS Petrochemical Index reverse their recent 8% decline, the margin expansion narrative would face a direct challenge.
For retail investors, the upgrade highlights a specific investment theme within the industrial sector: favoring companies with strong brand and formulation advantages that allow them to pass on costs. Retail portfolios with broad materials sector ETFs like XLB will have limited exposure, making direct stock selection more relevant. The $105 price target offers a concrete benchmark for evaluating the stock’s performance over the next 12-18 months against broader market returns.
H.B. Fuller’s average annual EBITDA growth over the past five fiscal years is approximately 6%. A 14% forecast for FY2027 is more than double that historical rate. The last time the company posted growth above 12% was in FY2021, which was a rebound year from pandemic lows. Achieving this growth in a stable, non-recovery environment would represent a significant acceleration driven by operational improvements rather than just cyclical uplift.
The company’s primary raw material inputs are petroleum-based derivatives, including ethylene, propylene, and vinyl acetate monomer. These inputs can constitute 40-50% of its cost of goods sold. Recent stability in natural gas prices, a key feedstock for ethylene production, has been a major contributor to improved cost visibility. Monitoring the monthly PPI for Industrial Chemicals provides a reliable proxy for these cost pressures.
J.P. Morgan’s upgrade reflects a conviction that H.B. Fuller’s operational shifts will deliver materially faster profit growth than the market currently prices.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.